Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26472021)

  • 1. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
    Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
    Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
    Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Ardini E; Bosotti R; Amatu A; Valtorta E; Somaschini A; Raddrizzani L; Palmeri L; Banfi P; Bonazzina E; Misale S; Marrapese G; Leone A; Alzani R; Luo D; Hornby Z; Lim J; Veronese S; Vanzulli A; Bardelli A; Martignoni M; Davite C; Galvani A; Isacchi A; Siena S
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26563355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
    Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH
    Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
    Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A
    Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
    Russo M; Misale S; Wei G; Siravegna G; Crisafulli G; Lazzari L; Corti G; Rospo G; Novara L; Mussolin B; Bartolini A; Cam N; Patel R; Yan S; Shoemaker R; Wild R; Di Nicolantonio F; Bianchi AS; Li G; Siena S; Bardelli A
    Cancer Discov; 2016 Jan; 6(1):36-44. PubMed ID: 26546295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Foretinib Overcomes Entrectinib Resistance Associated with the
    Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
    Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
    [No Abstract]   [Full Text] [Related]  

  • 8. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
    Wu S; Liu Y; Shi X; Zhou W; Zeng X
    Dig Liver Dis; 2023 Dec; 55(12):1757-1764. PubMed ID: 37142453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
    Créancier L; Vandenberghe I; Gomes B; Dejean C; Blanchet JC; Meilleroux J; Guimbaud R; Selves J; Kruczynski A
    Cancer Lett; 2015 Aug; 365(1):107-11. PubMed ID: 26001971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
    Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
    Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
    Chou A; Fraser T; Ahadi M; Fuchs T; Sioson L; Clarkson A; Sheen A; Singh N; Corless CL; Gill AJ
    Mod Pathol; 2020 May; 33(5):924-932. PubMed ID: 31792356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
    Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y
    J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.
    Dong K; Yin L; Wang Y; Jia L; Diao X; Huang X; Zhou L; Lin D; Sun Y
    Hum Pathol; 2024 Jun; 148():87-92. PubMed ID: 38653403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRKA expression and
    Mauri G; Valtorta E; Cerea G; Amatu A; Schirru M; Marrapese G; Fiorillo V; Recchimuzzo P; Cavenago IS; Bonazzina EF; Motta V; Lauricella C; Veronese S; Tosi F; Maiolani M; Rospo G; Truini M; Bonoldi E; Christiansen J; Potts SJ; Siena S; Sartore-Bianchi A
    J Clin Pathol; 2018 Oct; 71(10):926-931. PubMed ID: 29802225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R
    Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539
    [No Abstract]   [Full Text] [Related]  

  • 20. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.